Biologic Agents
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 11 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 11 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03508713 (ClinicalTrials.gov) | May 13, 201820180513 | 4/6/201720170604 | Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND) Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR G ... | Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR G ... | Rheumatoid Arthritis | Drug: disease modified antirheumatic drugs or biological agents | Nanfang Hospital of Southern Medical University | Southern Medical University, China | Not yet recruiting | 18 Years | N/A | All | 200 | NULL | |
| 2 | NCT03470688 (ClinicalTrials.gov) | March 1, 201820180301 | 6/3/201820180306 | Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents | An Observational Study Designed to Investigate the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents in Australian Rheumatology An Observational Study Designed to Investigate the Utilisation and Effectiveness of Originator and B ... | Rheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis | Biological: Originator;Biological: Biosimilar | Opal Rheumatology Ltd. | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | N/A | All | 5000 | Australia | |
| 3 | NCT03288584 (ClinicalTrials.gov) | October 27, 201720171027 | 16/9/201720170916 | Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheuma ... | The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Function in Patients With Rheumatoid Arthritis The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Fun ... | Rheumatoid Arthritis;Inflammation | Drug: Tocilizumab (Actemra®);Drug: Other biological agent;Drug: Corticosteroid and non-biological agents. Drug: Tocilizumab (Actemra®);Drug: Other biological agent;Drug: Corticosteroid and non-biological ag ... | University of Athens | NULL | Recruiting | 18 Years | 80 Years | All | 60 | Greece | |
| 4 | NCT02311855 (ClinicalTrials.gov) | August 201420140800 | 4/12/201420141204 | Duration of Immune Response to Influenza Vaccination in Patients With RA | Duration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving Treatment With Biologic Agents Duration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving ... | Rheumatoid Arthritis | Biological: Influenza vaccine | Bassett Healthcare | New York State Department of Health | Completed | 40 Years | 75 Years | All | 87 | Phase 4 | United States |
| 5 | NCT01907230 (ClinicalTrials.gov) | September 10, 201320130910 | 14/7/201320130714 | Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients | Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Propylactic Use of Entecavir for Biological AgentsAssociated Hepatitis B Virus Reactivation in Infla ... | Rheumatoid Arthritis;Hepatitis B Reactivation;Exposure to Hepatitis B Virus | Drug: Entecavir | Taipei Veterans General Hospital, Taiwan | NULL | Active, not recruiting | 20 Years | 90 Years | All | 115 | Phase 4 | Taiwan |
| 6 | NCT01770379 (ClinicalTrials.gov) | October 201220121000 | 16/10/201220121016 | Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFa Agents. Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response ... | A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFa Agents A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinum ... | Rheumatoid Arthritis | Biological: Secukinumab (AIN457);Biological: Placebo | Novartis Pharmaceuticals | NULL | Terminated | 18 Years | N/A | All | 242 | Phase 3 | United States;Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;Ecuador;Puerto Rico United States;Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Germany;Greece;Guatemala;I ... |
| 7 | NCT01870908 (ClinicalTrials.gov) | August 201220120800 | 4/6/201320130604 | Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients | Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biologic ... | Rheumatoid Arthritis | Drug: tacrolimus;Drug: biological agents | Astellas Pharma Inc | NULL | Completed | N/A | N/A | Both | 664 | N/A | Japan |
| 8 | NCT01350804 (ClinicalTrials.gov) | September 201120110900 | 9/5/201120110509 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor a (Anti-TNFa) Agents (CAIN457F2309 and CAIN457F2309E1) Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Pati ... | A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFa Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1) A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the E ... | Rheumatoid Arthritis | Biological: AIN457;Biological: Placebo;Biological: Abatacept | Novartis Pharmaceuticals | NULL | Completed | 18 Years | N/A | All | 551 | Phase 3 | United States;Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain United States;Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Rom ... |
| 9 | NCT01377012 (ClinicalTrials.gov) | August 30, 201120110830 | 17/6/201120110617 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFa Agents Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (A ... | A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFa Agents (CAIN457F2302) and a Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2302E1) A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 2 ... | Rheumatoid Arthritis | Biological: Secukinumab (AIN457);Biological: Placebo | Novartis Pharmaceuticals | NULL | Completed | 18 Years | N/A | All | 637 | Phase 3 | United States;Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Puerto Rico;Thailand;Turkey;United Kingdom;Peru;Romania United States;Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Pu ... |
| 10 | NCT03496831 (ClinicalTrials.gov) | January 1, 200620060101 | 5/4/201820180405 | Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biolo ... | Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic In ... | Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis | Drug: Biologic Agents | Simon Krabbe | University of Aarhus;Zealand University Hospital;University of Southern Denmark | Completed | 18 Years | N/A | All | 7500 | NULL |